← Back to Clinical Trials
Recruiting NCT06553131

NCT06553131 Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06553131
Status Recruiting
Phase
Sponsor Loma Linda University
Condition Neuromuscular Blockade
Study Type OBSERVATIONAL
Enrollment 32 participants
Start Date 2024-12-26
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
Neuromuscular Transmission Monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 32 participants in total. It began in 2024-12-26 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Medications used to relax the muscles are used during surgery. The amount of muscle relaxation can monitored with devices that stimulate a specific nerve and evaluate the muscle response. The response to, and recovery from, medications that relax the muscles are best described for a nerve in the arm called the ulnar nerve. The investigators believe that other nerves in the arm, such as the median nerve, could be used to monitor the amount of muscle relaxation. The purpose of this study is to compare the muscle response at two different nerve sites after giving medications to relax the muscles. This study is going to measure the depth of muscle relaxation during surgery at two different sites. The muscle response to stimulation of the ulnar nerve (located in the arm) will be compared to the muscle response to stimulation of the median nerve (also located in the arm).

Eligibility Criteria

Inclusion Criteria: * Adults 18 - 75 years of age who are able to provide consent * Scheduled for elective surgery requiring muscle relaxation, in a supine position under general anesthesia, with an anticipated duration of at least 1.5 hours Exclusion Criteria: * Contraindication to rocuronium use * Comorbidities that may prolong the duration of neuromuscular blockade or alter pharmacodynamics and/or pharmacokinetics, such as: * Neuromuscular disease * Expected or known difficult airway * Rocuronium allergy * BMI \< 18.5 or \> 40 * History of adhesive allergy * Upper extremity weakness, limb deformity, or absence of all or part of an upper limb * Patients undergoing surgical procedures requiring cardiopulmonary bypass

Contact & Investigator

Central Contact

Melissa D McCabe, MD, MSCR

✉ mmccabe@llu.edu

📞 909 558 4475

Principal Investigator

Michael Benggon, MD

PRINCIPAL INVESTIGATOR

Loma Linda University

Frequently Asked Questions

Who can join the NCT06553131 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Neuromuscular Blockade. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06553131 currently recruiting?

Yes, NCT06553131 is actively recruiting participants. Contact the research team at mmccabe@llu.edu for enrollment information.

Where is the NCT06553131 trial being conducted?

This trial is being conducted at Loma Linda, United States.

Who is sponsoring the NCT06553131 clinical trial?

NCT06553131 is sponsored by Loma Linda University. The principal investigator is Michael Benggon, MD at Loma Linda University. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology